A review of human papillomavirus vaccines: From basic science to clinical trials

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Berry, J Michael ^a   Palefsky, Joel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anal Cancer; Anogenital Neoplasia; Cervical Cancer; Fusion Protein; Heat Shock Protein; Human Papillomavirus Vaccines; Plasmid DNA Vaccine; Review; Squamous Intraepithelial Lesion; Virus Like Particle

Indexed keywords

ANTIRETROVIRUS AGENT; CAPSID PROTEIN; HEAT SHOCK PROTEIN; HYBRID PROTEIN; PLASMID DNA; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS VACCINE; PAPILLOMA VIRUS VACCINE;

ANUS CANCER; CLINICAL TRIAL; CONDYLOMA; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; FATIGUE; FEVER; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MALAISE; NONHUMAN; PROPHYLAXIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE; TUMOR REGRESSION; UTERINE CERVIX CANCER; VACCINIA VIRUS; VIRUS INFECTION; WART VIRUS; ANIMAL; CLASSIFICATION; DISEASE MODEL; IMMUNOLOGY; PAPILLOMA VIRUS; PATHOGENICITY; SYNTHESIS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; VACCINIA VIRUS;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; VIRAL VACCINES;

EID: 0042945766     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1003     Document Type: Review

References (48)

1. zur Hausen, H. Papillomaviruses in human cancers. Proc Assoc Am Physicians. 111, 581-587 (1999)
2. Frisch, M., B. Glimelius, A. J. van den Brule, J. Wohlfahrt, C. J. Meijer, J. M. Walboomers, S. Goldman, C. Svensson, H. O. Adami, & M. Melbye. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 337, 1350-1358 (1997)
3. Palefsky, J. M. & E. A. Holly. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev. 4, 415-428. (1995)
4. Moscicki, A. B., S. Shiboski, J. Broering, K. Powell, L. Clayton, N. Jay, T. M. Darragh, R. Brescia, S. Kanowitz, S. B. Miller, J. Stone, E. Hanson, & J. Palefsky. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 132, 277-284 (1998)
5. Stern, P. L., M. Brown, S. N. Stacey, H. C. Kitchener, I. Hampson, E. S. Abdel-Hady, & J. V. Moore. Natural HPV immunity and vaccination strategies. J Clin Virol. 19, 57-66 (2000)
6. Nakagawa, M., D. P. Stites, S. Patel, S. Farhat, M. Scott, N. K. Hills, J. M. Palefsky, & A. B. Moscicki. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis. 182, 595-598 (2000)
7. Bontkes, H. J., T. D. de Gruijl, A. J. van den Muysenberg, R. H. Verheijen, M. J. Stukart, C. J. Meijer, R. J. Scheper, S. N. Stacey, M. F. Duggan-Keen, P. L. Stern, S. Man, L. K. Borysiewicz, & J. M. Walboomers. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer. 88, 92-98 (2000)
8. Scott, M., M. Nakagawa, & A. B. Moscicki. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 8, 209-220 (2001)
9. Penn, I. Cancers of the anogenital region in renal transplant recipients. Cancer. 58, 611-616 (1986)
10. Palefsky, J. M. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women. Semin Oncol. 27, 471-479 (2000)
11. Biggar, R. J. & C. S. Rabkin. The epidemiology of AIDS - related neoplasms. Hematol Oncol Clin North Am. 10, 997-1010 (1996)
12. Williams, A. B., T. M. Darragh, K. Vranizan, C. Ochia, A. R. Moss, & J. M. Palefsky. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 83, 205-211. (1994)
13. Wright, T. C., Jr., T. V. Ellerbrock, M. A. Chiasson, N. Van Devanter, & X. W. Sun. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol. 84, 591-597. (1994)
14. Sun, X. W., L. Kuhn, T. V. Ellerbrock, M. A. Chiasson, T. J. Bush, & T. C. Wright, Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 337, 1343-1349. (1997)
15. Holly, E. A., M. L. Ralston, T. M. Darragh, R. M. Greenblatt, N. Jay, & J. M. Palefsky. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 93, 843-849 (2001)
16. Conley, L. J., T. V. Ellerbrock, T. J. Bush, M. A. Chiasson, D. Sawo, & T. C. Wright. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 359, 108-113. (2002)
17. Palefsky, J. M., E. A. Holly, M. L. Ralston, N. Jay, J. M. Berry, & T. M. Darragh. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. Aids. 12, 495-503. (1998)
18. Palefsky, J. M., E. A. Holly, M. L. Ralston, S. P. Arthur, N. Jay, J. M. Berry, M. M. DaCosta, R. Botts, & T. M. Darragh. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 17, 320-326. (1998)
19. Palefsky, J. M., E. A. Holly, C. J. Hogeboom, M. L. Ralston, M. M. DaCosta, R. Botts, J. M. Berry, N. Jay, & T. M. Darragh. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 17, 314-319. (1998)
20. Palefsky, J. M., E. A. Holly, M. L. Ralston, M. Da Costa, H. Bonner, N. Jay, J. M. Berry, & T. M. Darragh. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr. 28, 422-428. (2001)
21. Schiller, J. T. & A. Hidesheim. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol. 19, 67-74 (2000)
22. Valone, F. H., E. Small, M. MacKenzie, P. Burch, M. Lacy, M. V. Peshwa, & R. Laus. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 7 Suppl 2, S53-61 (2001)
23. Breitburd, F. & P. Coursaget. Human papillomavirus vaccines. Semin Cancer Biol. 9, 431-444 (1999)
24. Harro, C. D., Y. Y. Pang, R. B. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, & D. R. Lowy. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 93, 284-292 (2001)
25. Herrero, R., A. Hildesheim, C. Bratti, M. Schiffman, A. C. Rodriguez, S. Wacholder, E. Freer, J. Schiller, & D. Lowy. Rationale and design of the NCI-Costa Rica HPV 16 vaccine trial. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-94 (2001)
26. Nardelli-Haefliger, D., D. Wirthner, J. Schiller, D. Lowy, F. Hartmann, & P. DeGrand. Antibody responses in cervical secretions of female volunteers after intramuscular vaccination with purified HPV 16 VLPS. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2007, O-52 (2001)
27. Nardelli-Haefliger, D., F. Lurati, D. Wirthner, F. Spertini, J. Schiller, D. Lowy, F. Hartmann, & P. DeGrand. Mucosal vaccination of female volunteers with purified HPV 16 VLPS. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-103 (2001)
28. Brown, D. R., K. A. Ault, C. Wheeler, K. U. Jansen, J. F. Smith, E. Barr, A. Dicello, M. R. Nelson, & R. Railkar. A dose-ranging study of the safety and immunogenicity profiles of a quadrivalent HPV (types 6, 11, 16, and 18) L1 VLP candidate vaccine in young healthy women. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, O-51 (2001)
29. Koutsky, L. A., L. R. Miller, G. A. Poland, R. Jacobson, G. Suhr, L. Chiacchierini, E. Barr, & K. Jansen. Persistence of HPV 16 antibodies after immunization with HPV 16 L1 virus-like particle (VLP) vaccines. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2007, O-50 (2001)
30. Wheeler, C., D. Brown, K. Fife, J. F. Smith, A. Dicello, R. Wang, E. Barr, G. Suhr, L. Chiacchierini, & K. Jansen. A phase I study of the safety/tolerability and immunogenicity profiles of research lot HPV 11 L1 virus-like particle (VLP) vaccine: persistence of anti-HPV 11 responses. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-90 (2001)
31. van Driel, W. J., M. E. Ressing, G. G. Kenter, R. M. Brandt, E. J. Krul, A. B. van Rossum, E. Schuuring, R. Offringa, T. Bauknecht, A. Tamm-Hermelink, P. A. van Dam, G. J. Fleuren, W. M. Kast, C. J. Melief, & J. B. Trimbos. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 35, 946-952. (1999)
32. Ressing, M. E., W. J. van Driel, R. M. Brandt, G. G. Kenter, J. H. de Jong, T. Bauknecht, G. J. Fleuren, P. Hoogerhout, R. Offringa, A. Sette, E. Celis, H. Grey, B. J. Trimbos, W. M. Kast, & C. J. Melief. Detection of T helper responses, but not of human papillomavirus- specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 23, 255-266. (2000)
33. Muderspach, L., S. Wilczynski, L. Roman, L. Bade, J. Felix, L. A. Small, W. M. Kast, G. Fascio, V. Marty, & J. Weber. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 6, 3406-3416. (2000)
34. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Stacey, M. E. Boursnell, E. Rutherford, J. K. Hickling, & S. C. Inglis. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347, 1523-1527. (1996)
35. Adams, M., L. Borysiewicz, A. Fiander, S. Man, B. Jasani, H. Navabi, C. Lipetz, A. S. Evans, & M. Mason. Clinical studies of human papilloma vaccines in preinvasive and invasive cancer. Vaccine. 19, 2549-2556. (2001)
36. Davidson, E., A. Tomlinson, P. Stern, J. Dobson, L. Lack, J. S. Roberts, C. Boswell, J. Hickling, & H. Kitchener. A phase II trial to assess the safety, immunogenicity and efficacy of TA-HPV in patients with high grade vulvar intraepithelial neoplasia (VIN) Proceedings of the 19th International Papillomavirus Conference, Sept 1-7, 2001, P-88 (2001)
37. Xenova. Xenova Group plc press release: successful results of phase IIa trial for therapeutic vaccine TA-HPV. http://www.xenova.co.uk/PressReleases/ pr_20020327_01.html, (2002)
38. O'Neil, T., Y. Khan, S. E. Chisholm, N. W. Whittle, L. C. Jack, J. S. Roberts, & J. K. Hickling. Safety and immunogenicity of an HPV 16L2E7E6 fusion protein vaccine (TA-CIN) in a phase I clinical trial. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-100 (2001)
39. Burg, S. V. d., A. deJong, K. Kwappenberg, A. Y. Khan, C. Melief, T. O'Neil, J. Hickling, & R. Offringa. Induction of HPV16-specific T-cell immunity in healthy volunteers: a phase I/II study with the recombinant HPV 16 L2E6E7 fusion protein vaccine TA-CIN. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-91 (2001)
40. Gerard, C. M., N. Baudson, K. Kraemer, C. Bruck, N. Garcon, Y. Paterson, Z. K. Pan, & D. Pardoll. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine. 19, 2583-2589. (2001)
41. Hallez, S., F. Maudoux, F. Buxant, I. Fayt, A. Burny, J.-C. Noel, & P. Simon. Use of cytokine flow cytometry to monitor cellular immune reponse to an HPV 16 E7-derived vaccine: phase I/II trial in women with HPV 16 positive grade 3 cervical intraepithelial neoplasia. Proceedings of the 19th International Papillomavirus Confernence, Sept 1-7, 2001, P-98 (2001)
42. Palefsky, J. M., E. A. Holly, C. J. Hogeboom, J. M. Berry, N. Jay, & T. M. Darragh. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol. 14, 415-422 (1997)
43. Jay, N., J. M. Berry, C. J. Hogeboom, E. A. Holly, T. M. Darragh, & J. M. Palefsky. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum. 40, 919-928 (1997)
44. Berry, J. M. & J. M. Palefsky. Pathogenesis and clinical manifestations of HIV-associated anogenital neoplasia. In: The AIDS knowledge base: a textbook on HIV disease from the University of California, San Francisco School of Medicine, and the San Francisco General Hospital. P. T. Cohen, M. A. Sande, & P. A. Volberding (Eds.) Philadelphia, PA: Lippincott Williams & Wilkins, (1999)
45. Chang, G. J., J. M. Berry, N. Jay, J. M. Palefsky, & M. L. Welton. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 45, 453-458 (2002)
46. Palefsky, J. M., S. E. Goldstone, M. T. Winnett, M. I. Siegel, & J. R. Neefe. HspE7 treatment of anal dysplasia: results of an open label trial of HspE7 and comparison with a prior controlled trial of low dose HspE7. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, IL, Dec. 16-19, 2001, (2001)
47. Chu, N. R., H. B. Wu, T. Wu, L. J. Boux, M. I. Siegel, & L. A. Mizzen. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 121, 216-225 (2000)
48. Klencke, B., M. Matijevic, R. G. Urban, J. L. Lathey, M. L. Hedley, M. Berry, J. Thatcher, V. Weinberg, J. Wilson, T. Darragh, N. Jay, M. Da Costa, & J. M. Palefsky. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 8, 1028-1037 (2002)